SCHEMBL11520320

SCHEMBL11520320

CCCCOC(=O)C(O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.54
ALDH1A1 P00352 1/20 0.52
HCAR2 Q8TDS4 3/20 0.52
TSHR P16473 3/20 0.45
HPGD P15428 1/20 0.45
GPR84 Q9NQS5 3/20 0.42
NAAA Q02083 1/20 0.42
FFAR1 O14842 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
EPHX1 P07099 1/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943644 0.94 HCAR2 (0.53) ATMALDH1A1HCAR2TSHRGPR84
SCHEMBL11670364 0.92 HCAR2 (0.55) ATMALDH1A1HCAR2TSHRGPR84
SCHEMBL9222386 0.92 HCAR2 (0.55) ATMALDH1A1HCAR2TSHRGPR84
SCHEMBL5792770 0.89 ALDH1A1 (0.58) ATMALDH1A1HCAR2TSHRHPGD
SCHEMBL6670948 0.86 HCAR2 (0.48) ATMALDH1A1HCAR2TSHRGPR84
SCHEMBL1274269 0.81 ALDH1A1 (0.50) ATMALDH1A1HCAR2TSHRHPGD
SCHEMBL8030448 0.81 ALDH1A1 (0.50) ATMALDH1A1HCAR2TSHRHPGD
SCHEMBL30616870 0.81 ALDH1A1 (0.50) ATMALDH1A1HCAR2TSHRHPGD
Cadaverine Tartrate SCHEMBL27991307 0.81 ALDH1A1 (0.50) ATMALDH1A1HCAR2TSHRHPGD
Cadaverine Tartrate SCHEMBL27555419 0.81 ALDH1A1 (0.50) ATMALDH1A1HCAR2TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
WO-2024063100-A1 METHOD FOR PRODUCING POLYVALENT CARBODIIMIDE B 旭化成株式会社 2024-03-28 WO disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed
EP-4130154-A1 CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT Asahi Kasei Kabushiki Kaisha (JP) 2023-02-08 EP disclosed
CN-115190901-A Carbodiimide composition, curing agent composition, coating composition, and resin cured product 旭化成株式会社 2022-10-14 CN disclosed
US-4150069-A DETERGENT BUILDERS MONSANTO COMPANY (US) 1979-04-17 US disclosed
US-4005189-A Process of suppressing odors employing deodorants containing esters of aliphatic hydroxycarboxylic acids HENKEL & CIE G.M.B.H. (DT) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 ATM 1103/4885ALDH1A1 737/4885HCAR2 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.